319 696

Cited 5 times in

Survival Estimates after Stopping Sorafenib in Patients with Hepatocellular Carcinoma: NEXT Score Development and Validation

DC Field Value Language
dc.contributor.author김도영-
dc.contributor.author김범경-
dc.contributor.author김승업-
dc.contributor.author박준용-
dc.contributor.author안상훈-
dc.contributor.author이혜원-
dc.contributor.author전미영-
dc.contributor.author한광협-
dc.date.accessioned2018-07-20T11:58:44Z-
dc.date.available2018-07-20T11:58:44Z-
dc.date.issued2017-
dc.identifier.issn1976-2283-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/161574-
dc.description.abstractBackground/Aims: Limited information is available regarding patient survival after sorafenib discontinuation in patients with hepatocellular carcinoma (HCC). Thus, we developed and validated a novel survival prediction model. Methods: Clinical data from 409 patients with HCC who stopped taking sorafenib between September 2008 and February 2015 were reviewed. Results: In the training cohort, four factors were independent negative predictors of survival (p<0.05). Based on the β regression coefficient of each factor, we established the NEXT score (Survival after Stopping Nexavar Treatment), allocating 1 point each for an Eastern Cooperative Oncology Group score ≥2, Child-Pugh class B or C, serum sodium ≤135 mEq/L, and α-fetoprotein 〉400 ng/mL. Area under the receiver operating characteristic curve values to predict 1-, 3-, and 6-month survival rates were 0.805, 0.809, and 0.774, respectively, in the training cohort and 0.783, 0.728, and 0.673, respectively, in the validation cohort (n=137). When the training and validation cohorts were stratified into three risk groups (NEXT score 0 [low-risk] vs 1 to 2 [intermediate-risk] vs 3 to 4 [high-risk]), survival differed significantly between the groups (p<0.05, log-rank test). Conclusions: In patients with HCC, survival after stopping sorafenib is poor. However, risk estimates based on a new "NEXT score" may help predict survival and prognosis even in patients who discontinue sorafenib treatment.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherEditorial Office of Gut and Liver-
dc.relation.isPartOfGUT AND LIVER-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAged-
dc.subject.MESHAntineoplastic Agents*-
dc.subject.MESHArea Under Curve-
dc.subject.MESHCarcinoma, Hepatocellular/drug therapy-
dc.subject.MESHCarcinoma, Hepatocellular/mortality*-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHLiver Neoplasms/drug therapy-
dc.subject.MESHLiver Neoplasms/mortality*-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNiacinamide/analogs & derivatives*-
dc.subject.MESHPhenylurea Compounds*-
dc.subject.MESHROC Curve-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHRisk Factors-
dc.subject.MESHSeverity of Illness Index*-
dc.subject.MESHSurvival Rate-
dc.subject.MESHWithholding Treatment/statistics & numerical data*-
dc.titleSurvival Estimates after Stopping Sorafenib in Patients with Hepatocellular Carcinoma: NEXT Score Development and Validation-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Internal Medicine-
dc.contributor.googleauthorHye Won Lee-
dc.contributor.googleauthorHyun Soo Kim-
dc.contributor.googleauthorSeung Up Kim-
dc.contributor.googleauthorDo Young Kim-
dc.contributor.googleauthorBeom Kyung Kim-
dc.contributor.googleauthorJun Yong Park-
dc.contributor.googleauthorSang Hoon Ahn-
dc.contributor.googleauthorMi Young Jeon-
dc.contributor.googleauthorJa Yoon Heo-
dc.contributor.googleauthorSoo Young Park-
dc.contributor.googleauthorYu Rim Lee-
dc.contributor.googleauthorSun Kyung Jang-
dc.contributor.googleauthorSu Hyun Lee-
dc.contributor.googleauthorSe Young Jang-
dc.contributor.googleauthorWon Young Tak-
dc.contributor.googleauthorKwang-Hyub Han-
dc.identifier.doi10.5009/gnl16391-
dc.contributor.localIdA00385-
dc.contributor.localIdA00487-
dc.contributor.localIdA00654-
dc.contributor.localIdA01675-
dc.contributor.localIdA02226-
dc.contributor.localIdA03318-
dc.contributor.localIdA05405-
dc.contributor.localIdA04268-
dc.relation.journalcodeJ00954-
dc.identifier.eissn2005-1212-
dc.identifier.pmid28651299-
dc.subject.keywordHepatocellular carcinoma-
dc.subject.keywordPrediction-
dc.subject.keywordRisk-
dc.subject.keywordSorafenib-
dc.subject.keywordSurvival-
dc.contributor.alternativeNameKim, Do Young-
dc.contributor.alternativeNameKim, Beom Kyung-
dc.contributor.alternativeNameKim, Seung Up-
dc.contributor.alternativeNamePark, Jun Yong-
dc.contributor.alternativeNameAhn, Sang Hoon-
dc.contributor.alternativeNameLee, Hye Won-
dc.contributor.alternativeNameJeon, Mi Young-
dc.contributor.alternativeNameHan, Kwang Hyup-
dc.contributor.affiliatedAuthorKim, Do Young-
dc.contributor.affiliatedAuthorKim, Beom Kyung-
dc.contributor.affiliatedAuthorKim, Seung Up-
dc.contributor.affiliatedAuthorPark, Jun Yong-
dc.contributor.affiliatedAuthorAhn, Sang Hoon-
dc.contributor.affiliatedAuthorLee, Hye Won-
dc.contributor.affiliatedAuthorJeon, Mi Young-
dc.contributor.affiliatedAuthorHan, Kwang Hyup-
dc.citation.volume11-
dc.citation.number5-
dc.citation.startPage693-
dc.citation.endPage701-
dc.identifier.bibliographicCitationGUT AND LIVER, Vol.11(5) : 693-701, 2017-
dc.identifier.rimsid61602-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.